Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia

INTRODUCTION: People who are immunocompromised have a poor biological response to vaccinations. This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Barber, Vicki S, Peckham, Nicholas, Duley, Lelia, Francis, Anne, Abhishek, Abhishek, Moss, Paul, Cook, Jonathan A, Parry, Helen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546125/
https://www.ncbi.nlm.nih.gov/pubmed/37770269
http://dx.doi.org/10.1136/bmjopen-2023-077946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546125/
https://www.ncbi.nlm.nih.gov/pubmed/37770269
http://dx.doi.org/10.1136/bmjopen-2023-077946

Ejemplares similares